Sepideh Babaniamansour; Nazanin Ershadinia; Ehsan Aliniagerdroudbari; Amirmohammad Babaniamansour; Atieh Masali; Alireza Entezari
Abstract
Introduction:Hyperthyrotropinemia (HT) can be transient or permanent. There is no specific protocol in confirmatory tests to discriminate between transient and permanent forms. The aim of this study was to investigate the prevalence of transient HT and the factors that help to discriminate transient ...
Read More
Introduction:Hyperthyrotropinemia (HT) can be transient or permanent. There is no specific protocol in confirmatory tests to discriminate between transient and permanent forms. The aim of this study was to investigate the prevalence of transient HT and the factors that help to discriminate transient from permanent HT. Methods:This was an observational prospective study in all neonates diagnosed with HT referred to the pediatric clinic of Boali Hospital, affiliated to Islamic Azad University Tehran Faculty of Medicine, Tehran, Iran during September 2017 and January 2019. The recovery rate was investigated during a three-month follow-up while withholding medical treatment. Data were analyzed with SPSS Version 22.0.Results: Totally, 80 neonates (65% girls) were enrolled in this study. Among them, 62 participants (77.5%) recovered without any treatment during the three months of follow-up. The recovery rate was significantly higher in term newborns (p < 0.01). The mean weight of recovered neonates (2767.7 ± 440.2 gr) was significantly higher than that of the neonates who did not recover (2141.7 ± 755.2) (p < 0.01). The mean level of thyroid-stimulating hormone (TSH) of the recovered neonates (9.4 ± 3.0 mIU/L) was significantly lower than in the neonates who did not recover (22 ± 6.5 mIU/L) (p < 0.01). Conclusion: The outcome of HT became mostly permanent in patients with a higher level of TSH. The prematurity and low birth weight were the influential factors on TSH level, which could indirectly increase the risk of HT permanence.
Somayyeh Hashemian; Ashraf Mohammad zadeh; Alireza Ataee nakhaei
Abstract
Hyperbilirubinemia is a common disease and unconjugated hyperbilirubinemia has been seen mainly in neonates. Severe form of unconjugated hyperbilirubinemia may cause kernicterus and even death. Conventional treatment for severe unconjugated hyperbilirubinemia consists of phototherapy and exchange transfusion ...
Read More
Hyperbilirubinemia is a common disease and unconjugated hyperbilirubinemia has been seen mainly in neonates. Severe form of unconjugated hyperbilirubinemia may cause kernicterus and even death. Conventional treatment for severe unconjugated hyperbilirubinemia consists of phototherapy and exchange transfusion that have several known disadvantages; specially exchange transfusion is associated with a significant morbidity and even mortality. These harmful effects indicate the need to develop alternative pharmacological treatment strategies for unconjugated hyperbilirubinemia. One of these pharmacological agents is zinc salts. Zinc has been shown to lower the bilirubin levels by inhibition of the enterohepatic cycling of unconjugated bilirubin. Oral zinc has been shown to reduce serum unconjugated bilirubin in animals, adolescents and low birth weight neonates. However, studies in healthy term neonates given oral zinc showed no reduction in hyperbilirubinemia based on daily measurement. In order to improve the accuracy, hyperbilirubinemia may be determined based on measurements every hour. More studies are needed to know the effect of zinc in neonatal jaundice.